Expect to See DOACs for Venous Thromboembolism Due to Cancer

You'll continue to see a shift toward direct oral anticoagulants (Eliquis, etc) for cancer-associated venous thromboembolism (VTE).

We're used to seeing these patients on a low-molecular-weight heparin (LMWH), such as enoxaparin...or warfarin as an alternative.

But evidence with DOACs is stacking up for VTE due to cancer.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote